TB-500 (Thymosin Beta-4) — what the research says about tissue repair

Every cell in the body holds a protein whose abundance exceeds all other cytoskeletal proteins combined. Actin — that is the protein — is responsible for cell shape, motility, division, migration. Without actin, a cell cannot heal a wound, repair damaged tissue, or escape from an inflammation site. In 1981, Allan Goldstein and Ewald Hannappel of George Washington University isolated from calf thymus a small 43-amino-acid peptide that turned out to be the central regulator of actin dynamics in the cytoplasm. They named it Thymosin Beta-4 (Tβ4) — one of the key members of the recovery-peptide class, the fuller picture of which is covered in the how recovery peptides work review.

Four decades later Thymosin Beta-4 is one of the best-studied research peptides in the biomedical literature, with documented roles in skin wound healing, post-ischemic cardiac repair, and peripheral nerve regeneration. In the research-peptide trade, however, it travels under a different name: TB-500. The relationship between these two terms deserves its own paragraph.

📖 This article is educational and reviews the published scientific literature. The majority of the studies cited were conducted in animal models or in vitro. Where human clinical trial data exist, the fact is flagged explicitly. This is not medical advice.

TB-500 vs Thymosin Beta-4 — not exactly the same thing

In popular science and in research-peptide catalogs the terms “TB-500” and “Thymosin Beta-4” are often used interchangeably. From a strict chemical standpoint this is a simplification.

Thymosin Beta-4 (Tβ4) — the full, naturally occurring peptide, 43 amino acids in length. Sequence:

SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES

TB-500 — in its original meaning refers to a fragment of Tβ4, specifically the 7-amino-acid sequence LKKTETQ (positions 17–23 of the full peptide), together with stabilizing modifications. This fragment is responsible for the key biological activity of the full peptide — binding G-actin and modulating cytoskeletal dynamics.

In market practice “TB-500” in research-peptide catalogs typically denotes either the full Thymosin Beta-4 peptide or its stabilized version, even though the name technically refers to the fragment. A professional supplier should unambiguously specify the amino-acid sequence in the COA — that is the only unambiguous molecular identification.

The full Tβ4 peptide and the TB-500 fragment share a partially similar activity profile, but they differ in pharmacokinetics and potency in specific models. The bulk of the research concerns the full Tβ4, so the remainder of this article describes the scientific literature from the full-peptide standpoint.

TB-500 mechanism of action — actin dynamics and beyond

The main role of Thymosin Beta-4 in physiology is sequestration of monomeric actin (G-actin) — binding free monomer and regulating its availability for polymerization into filaments (F-actin). A single cell can contain millions of Tβ4 molecules, each bound to one G-actin molecule. The ratio of free to bound G-actin is the foundation of cytoskeletal dynamics control.

Key molecular mechanisms

• G-actin sequestration — Tβ4 binds G-actin and maintains a pool of free monomers ready for polymerization. When a cell needs a rapid shape change, migration, or division, G-actin availability is the limiting factor.
• Cell-migration modulation — through its effect on the cytoskeleton, Tβ4 regulates the migration of fibroblasts, endothelial cells, keratinocytes, and progenitor cells to the injury site (Goldstein et al., 2012).
• Angiogenesis stimulation — Tβ4 promotes the formation of new blood vessels through activation and migration of endothelial cells. This mechanism is central to wound healing and ischemic-tissue repair.
• Inflammatory state modulation — the peptide reduces expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-8) and modulates macrophage activation toward a repair phenotype (M2).
• Activation of progenitor-cell precursors — in cardiac-ischemia models Tβ4 reactivates a subpopulation of epicardial cells capable of differentiating into new vascular cells (Smart et al., 2007).

The four keys of regeneration

In the scientific literature Thymosin Beta-4 is sometimes described as a modulator of the “four key processes” of tissue healing:

See also our guide to regenerative peptides.

The combination of these four mechanisms explains why Tβ4 shows activity across such different injury models — from skin wounds to myocardial ischemia (Crockford et al., 2010).

State of the research — literature overview

The Thymosin Beta-4 bibliography includes hundreds of experimental papers across several main research areas. Some have reached the clinical-trial stage — which distinguishes Tβ4 from most recovery peptides that remain at the preclinical level.

Skin wound healing

This is one of the best-documented areas. Animal models showed:

• Accelerated wound closure — in rat and mouse full-thickness wound models, Tβ4 shortened healing time by 30–50% compared with the control group (Malinda et al., 1999)
• Improved regeneration quality — smaller scars, better collagen-fiber organization, greater mechanical strength of the regenerated tissue
• Efficacy in chronic wounds — diabetic ulcer and hard-to-heal wound models responded to Tβ4 better than to the control group

Based on these preclinical data, RegeneRx Biopharmaceuticals developed a Tβ4-based formulation (RGN-137) — a gel for chronic-wound treatment. Phase II and III trials produced mixed results — the formulation showed efficacy in some subgroups but did not achieve drug registration in major jurisdictions.

TB-500 and cardiac muscle repair

The second flagship area of Tβ4 research is cardiology. The paper by Bock-Marquette and colleagues (2004) published in Nature showed that Tβ4 protects cardiac muscle from ischemic damage and stimulates repair after a heart attack. The mechanism involves:

• Migration of progenitor cells from the epicardium into the myocardium
• Reactivation of developmental programs in epicardial cells
• Promotion of angiogenesis in the ischemic area
• Protection against cardiomyocyte apoptosis

Phase I and II trials of RGN-352 (an injectable Tβ4 formulation for acute myocardial infarction) provided safety signals but did not deliver unambiguous confirmation of clinical efficacy.

Corneal repair

Tβ4 showed activity in corneal injury models — it accelerated corneal epithelial healing after chemical and mechanical injury (Sosne et al., 2002). The RGN-259 formulation (eye drops) went through phase III trials in patients with neurotrophic keratitis and dry eye syndrome, and the biological activity of the formulation has been linked to functional fragments of the full peptide sequence (Sosne et al., 2010).

Peripheral nerve repair

Sciatic-nerve injury models in rats showed that Tβ4 promotes reinnervation, reduces Wallerian degeneration, and improves motor function at the injury site (Hannappel, 2007).

Skeletal muscle fiber repair

In skeletal-muscle injury models Tβ4 accelerated fiber regeneration, increased satellite cell activity, and improved the mechanical properties of the regenerated muscle. The effect was observed in both acute injury models and mouse muscular-dystrophy models.

Neurological models — stroke and brain injury

Single papers suggest a neuroprotective effect in ischemic stroke models in rats. Tβ4 reduced lesion area and improved motor function during the recovery period. The mechanism likely involves oligodendrocyte activation and remyelination (Morris et al., 2014).

Routes of administration in experiments

Across Thymosin Beta-4 studies, various administration routes have been used:

• Subcutaneous and intraperitoneal injection — most common in animal models
• Intravenous injection — in cardiac and neurological models
• Local application to the wound — in skin wound-healing models (with hydrogels or stabilizing formulations)
• Eye drops — in corneal models
• Inhalation — in isolated respiratory models

Unlike peptides from the BPC-157 range, Thymosin Beta-4 is not stable in the gastrointestinal tract — oral administration is not used in the main line of experimental research. The peptide must be administered parenterally to avoid proteolytic degradation.

Stability and storage

Thymosin Beta-4 requires the standard research-peptide storage protocol:

• Lyophilizate: stability of 18–24 months at -20°C
• Solution after reconstitution in bacteriostatic water: 14–28 days at 2–8°C
• Freeze-thaw cycle sensitivity: high — do not freeze the reconstituted solution
• pH sensitivity: best stability around neutral pH (6.5–7.5)

A full guide to peptide reconstitution and storage is available in the laboratory practice section.

Analytical specification of TB-500 from the One-Peptides catalog

TB-500 from the One-Peptides catalog — the TB-500 5 mg product — meets the following quality criteria:

Each vial is labeled with a batch number linked to a certificate of analysis (COA). Full QC documentation is available on the quality testing and certificates page.

Safety and limitations in light of the research

The toxicology profile of Thymosin Beta-4 in animal models is favorable — at therapeutic doses no significant organ toxicity was observed. In the clinical trials of RGN-137, RGN-352, and RGN-259 no major adverse events directly linked to the peptide were recorded.

Important caveats apply, however:

⚠️ Clinical trials of Tβ4-based formulations have not yet achieved drug registration in the major jurisdictions (EMA, FDA). Some trials produced safety signals but ambiguous efficacy. The peptide’s therapeutic status remains experimental.

Specific limitations:

• No drug approval — TB-500/Thymosin Beta-4 is not approved as a drug in any major jurisdiction
• WADA status — TB-500 is on the WADA prohibited list (category S2 — peptide growth factors). Athletes under anti-doping testing cannot use Tβ4 or its derivatives
• Hypothetical angiogenesis-related cancer concern — in animal models Tβ4 stimulated angiogenesis, which raises the question of potential impact on tumor progression. The data are not conclusive but they call for caution
• No long-term human data — most clinical trials involved short administration periods

FAQ — frequently asked questions

TB-500 is available in the One-Peptides catalog as the TB-500 5 mg variant — with full QC documentation.

ℹ️ Global disclaimer

All One-Peptides products are reagents intended exclusively for laboratory and scientific research (Research Use Only). They are not medicinal products, dietary supplements, or products intended for human consumption. The information in this article is educational and reviews the published scientific literature; it is not medical, pharmaceutical, or dietetic advice. Thymosin Beta-4 is on the WADA prohibited list — athletes under anti-doping testing cannot use the peptide.

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›